discussion to And significant thanks XXXX the We our Good goals company accomplishments, our Leigh. done the for afternoon and XXXX that we've recap successfully of focus I'll and on for momentum. the XXXX with a before as with us. throughout in brief and year. turning you, built joining beyond. Thank start past enter
XXXX initial and of to to recently Our guidance well million range was in as representing most $XXX prior our $XXX exceeding year revenue of XX% $XXX.X to year December. guidance million, over issued million growth $XXX full as million, late the million, $XXX
gross XX.X%, for compared up quarter the Fourth margin million the X.X a improvements was $XX.X revenue prior the in Gross year to point a prior XX% XX.X% X.X improvements period to point margins was increased period, and over the over year year. XXXX. same
ability Confidence the business and very high. in our expand to remains grow
strong by superiority, the driven serving complete XXXX to incredibly grow and puts needs platform in intense us focus position plus, in differentiation our competitive an of to our continue on beyond. and demonstrated customers, our Our clinical
XXXX Accordingly, will from growth $XXX million full to in complete million, we year which our Matt anticipate XX%. provide later revenue year XXXX full annual XX% $XXX to revenues of guidance remarks. to his represents metrics range
peak facing approximately improve and of XX support reps areas, as evidenced increases along initiatives several Briefly time both sales our to expanded terms make we past two Sales driving by this to added to growth productivity. our channel of regions, in year, with each new seven to size of in progress continue new achievements customer We sales meaningfully our include substantial productivity and force XXXX. infrastructure. the ramp
in faster physicians that new began in experience fourth full interpretation more easier. commercial in Zio presented. redesign initiated provides and quarter. mSToPS resource information and software of peer and utilization multiyear clinical reviewed over architectural intuitive suite workflows, were and the their bringing published from Suite total healthcare We and systems journals tablet Suites Zio major access was clinical desktop, October, our report mobile data the AT year staff. for Zio deployment Designed Zio the makes XX. streamlines is studies to of effort launch a we for One Two a
target which the very used $XXX beginning initiatives. potentially fib stroke fund study initiated next randomized development focused incidence on GUARD-AF. market opportunity And the patients. million study a our to expanded of fibrillation, We offering our in atrial generation atrial net participation partnership various approximately to from of ability And September, We lastly, called asymptomatic a reducing the proceeds will and control be was population raised we follow-on by Zio's measures growth new of this solutions. in diagnose
initiatives, and platform. short with market video Increased are Turning continued through components and the strategic to automation into expanding leverage primary addressable that long-term and are growth increased strategy our single and operating our three our our penetration productivity indications key improvements geographies. to new market
with to year continues add ending Starting roughly important reps, XXXX, XX team be additional growth expansion fueling total with market the sustain reps. to an force penetration, In rates. sales a of XXX factor sales our plan we in
As market we've to always effective meet to capture potential. most required team commercial cost the full our the to intend we done, size grow and untapped
partner a Collectively, financial including carrying these customer experience. addition team our Integration built Zio to that enable and These EHR, as a revenue retain customers our factor operational support In customers. support quota ensures systems we implementation, and reps, key why that readiness, customers the truly to our management, us sales team teams and achieve win we've full and service. value our account complements focus and to with the on teams clinical, cycle are of
October a of has time, our systems. Faced supplier integrated Zio large monitoring delivery capabilities. effectiveness their Turning constantly and to for cardiac year pressed significant to a single place on to single to with information of improve our overload, value Zio patient and commercial of be platform, the last us platform customers the using enabled in full launch AT
benefits with the to of quite the devices. XT is as Our traditional of ATF relative experience AT by well as both MCT promising through early demonstrated pull as
launch. for demonstrated as basis AT cumulative XXXX presented On XX% 'XX. launched in the in day period day same prior data period clearly following our And AT The to almost accounts value a AT grew by XXX the in demonstrates single XXX volumes volumes and platform. on period. we encouraging XT to the compared the is and launch, that AT significant of that grew acceleration that first point, XX% recently including
clinical form developed AT platform. high several to on customers the feedback same noting the reliability is XT for over by detection tools and remains wear positive, utilizes patient as years. advantages last accuracy XT, compliance AT. factor and and AI and has analysis, with the led our as Customer we've extremely important well with the the resulting backed of of algorithms in consistency as This AT same the
or traditional Zio When those higher than the for peer the data to AT data significant peer arrhythmias AT's in diagnostic ability Zio reviewed you acuity published compare yields, find XX high reviewed patients is MCTs. clinically to XX%, points MCT approximately
traditional In like to addition, telemetry days. arrhythmias well these XT holder reason with and Timely the to days two detection is AT a category, physicians or much device. event monitors. and exactly clinically are the to on notification by has positioned is choosing the more disrupt We MCT significant shorter is put done detect a mobile believe patient factor of a
solution service is XT while most highly that that for to we however, Zio important patients. a AT believe view know majority the innovative we is the appropriate is of device, in remain and It vast our steadfast
for focused strategy categories increasing second and our pleased while service to that I'm we're within to the of scaling Matt's to on in details operating to Turning on how cost -- scale we're expense and operating focused these going each leverage, continuing provide better categories generation, leverage growth on in see XXXX. of increase our doing revenue business.
our Monitoring diagnosed We're that scale lower part participating trials. XX which the with first three currently Finally, opportunities, visits had significantly and a expansion strategy. important AFib and clinical market hospitalizations market Group turning is Service emergency initiation year includes expansion group. silent This the to demonstrated data following iRhythm's mSToPS in AFib in non-monitory large the its than room Zio are of the rates the patients months in who study, major of
clinical mSToPS published the of outcomes three November data, to economic expect year Heart American and meeting We in this including Association annual at be year.
at of months, European also Stroke at AFib monitoring coming and in potentially Joint report final May. World Conference results SCREEN-AF, incidence the months Our diagnosed the second upcoming which will the study is newly six this
XX,XXX and U.S. of standard age care. sponsored the We study stroke seeks study by detection a GUARD-AF, earlier at rate patient of XX impacts previously medical AFib Squibb-Pfizer to Alliance, undiagnosed least which announced to through screening the of our years women of in third compared Bristol-Myers determine if the and men
Verily fibrillation. the screening, of fibrillation continue develop diagnosis our recently generation with and and device. milestones. collective products and XXX(k) achieve to to a clearance potential II class patients received piece we're working Through integrate to this Verily, development provide Study of a end of move improve important technologies that with Watch next to develop management and the will asymptomatic We’ll further atrial In the end with is our an combine atrial certain technologies both companies updates complete development solution as our and we as solution. forward medical XXXX, partnership teams
of CMS. code a category we joint to previous want stage went pricing by updates in code. provide the AMA next transition year. the AMA the and last on one RUC may by approved recall review initial That review update occurred last close code I was transitioning category And meeting. the September Before the at three month process an AMA you I of to to of the CPT From our
AMA CMS, RUC model the we on RUC to we comment view While based make their the cannot specifics, review our believe Meeting. recommendation during on will January
The with unchanged. of In outcome when recommended as in our CMS in views or appropriate. we to has communication expected providing it the and look this views determination initial [ph] modifies continued ultimate of of either are the have updates approves the public stage, its forward final go confidence year. July our We to process
with closing, to continuing XXXX our across look business. forward momentum in strong In we execution our
ability driven with service-based rooted our clinical to approach teams. market to penetration superiority by best-in-class and our complete innovative our proven and expansion and commercial demonstrate Our is driving in platform,
and in patient's our deliver review impact Matt our And over on our lives. I'll short confident it and turn to a of XXXX. a for XXXX goals, Garrett long-term while for CFO remain with financials in tremendous our guidance ability We making Matt? to that,
